Kimberly-clark Worldwide, Inc.

Shu-Ping Yang

Yanbin Huang

Lei Huang

Sharon Linda Greene

Kelly Davis Arehart

Ilona F Weart

Molly K Smith

Robert B Johnson

Stephen Quirk

Stephanie Michelle Martin

Curtis Sayre

Julie M Villanueva

John Gavin MacDonald

Xuedong Song

Kaiyuan Yang

Ning Wei

Jeffrey Eldon Fish

Sohail Malik

Rosann Marie Matthews Kaylor

Jai Kyung

Kelly Arehart

Sharon Greene

A composition for a medium that can discharges organic unsaturated colorant molecules that may stain is described. The composition can quickly and effectively neutralize a discoloration that results from, in particular, blood or blood-based, ink, or grease stains. The composition can remove the stain within, typically about 20-30 minutes, and can achieve color contrast of a &#x394;E value of about 15-20 or greater. The composition can be adapted for different uses and embodied in various cleaning, stain-fighting, cosmetic, personal hygiene, or medical products.

Colorant neutralizer

A biodegradable biodelivery device is disclosed. The biodelivery device is formed from a polymer comprising the reaction product of a polyol and a polyacid. When exposed to water, the polymer degrades through hydrolysis. Of particular advantage, the polymer can be formed so as to be elastic and flexible. In one embodiment, the polymer is formed into a vaginal insert. As the polymer degrades, the polymer releases acid to a vaginal environment for decreasing the pH of the environment.

Degradable therapeutic delivery device

The invention provides inhibitors of chondrosarcoma cell growth that are useful as anti-cancer and anti-tumor agents. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases and that can inhibit the activity of matrix metalloproteinases. The peptide inhibitors of the invention can be formulated into therapeutic compositions, lotions, creams and wound dressings.

Anti-chrondrosarcoma compounds

A vaginal treatment composition that rapidly forms a gel when placed into contact with monovalent or polyvalent cations, such as sodium (Na) and calcium (Ca) cations naturally found in vaginal mucosa, is provided. The gel may form in less than about 1 hour, in some embodiments less than about 1 minute, and in some embodiments, less than about 30 seconds. Among other things, such rapid gelation reduces the likelihood of leakage during use. In addition, because the gel may form intravaginally, it is more likely to retain its structure and shape over an extended period of time. In this manner, the gel may provide the prolonged release of a therapeutic agent that inhibits and/or treats vaginal infection. For instance, the gel may remain within the vagina for about 2 to about 48 hours to provide the desired effect.

Vaginal treatment composition containing xylitol

A therapeutic article includes a skin contact layer having a plurality of fibers forming a plurality of point-bearing surfaces configured for wear against a user's skin; a personal care composition disposed proximate the fibers; an external layer attached to the skin contact layer; and an intermediate layer interposed between the skin contact layer and the external layer, the intermediate layer being configured to activate the personal care composition, the external layer being configured to direct the activated personal care composition through the skin contact layer to treat the user.

Therapeutic article including a personal care composition and methods of making the therapeutic article

There is provided a new thermo-gelling composition made with methylcellulose and citric acid. This composition may also have an effective amount of a treating agent, which may be a medicinal agent, cosmetic agent, moisturizer, adjuvant, nutritional agent, other ingredients and combinations thereof. The composition is useful in delivering moisturizers or pharmaceutically active agents to the user in a controlled release manner through the mucosal tissues in a body cavity, or on body surfaces, or as a subcutaneously injected medicament. The composition may also be used as a replacement for the soft tissues of the body as in, for example, the foot cushion and cartilage repair.

Thermo-gelling composition

A vaginal treatment composition that employs a therapeutic agent to inhibit and/or treat vaginal infection is provided. The therapeutic agent is capable of inhibiting and/or killing(e.g.,),(e.g.,), and/or(e.g.,) pathogens. Desirably, such antimicrobial efficacy is achieved without substantially inhibiting the growth of Lactobacillus acidophilus. For instance, sugars and/or sugar alcohols may be employed in the present invention as a therapeutic agent for inhibiting and/or treating vaginal infection. In one particular embodiment, D-xylitol is used as the therapeutic agent.

Xylitol for treatment of vaginal infections

The present invention is directed to diagnostic devices and methods for detectinginfections.

Detection of trichomonas

The invention provides mannose phosphate and salts thereof for increasing vaginal cell growth, vaginal cell maturation and vaginal moisture, as well as compositions, articles and methods for treating and preventing vaginal conditions characterized by poor vaginal cell growth, low vaginal cell differentiation and low vaginal moisture.

Compositions for vaginal treatment

The present invention is directed to anti-microbial compositions and methods for treating fungal and yeast infections.

Anti-microbial composition and methods of use thereof

The invention provides hyaluronic acid compounds and derivatives thereof for preventing urogenital infections by a variety of pathogens, as well as compositions, articles and methods for treating and preventing urogenital infections.

Prevention of urogenital infections

A diagnostic test kit for detecting the presence or quantity of an enzyme or enzyme inhibitor is provided. The diagnostic kit utilizes reactive complexes to facilitate the detection of the enzyme or enzyme inhibitor. The reactive complexes include a substrate joined (e.g., covalently bonded, physically adsorbed, etc.) to a reporter and magnetic substance. In one embodiment, for example, a peptide, protein, or glycoprotein substrate is joined to a reporter (e.g., dyed latex particle) and magnetic particle. In this embodiment, the substrate provides a cleavage target for a proteolytic enzyme. Specifically, upon contacting the reactive complexes, the proteolytic enzyme cleaves the substrate and releases the reporter and/or magnetic particle. The signal exhibited by the released reporters may then be used to indicate the presence or quantity of an enzyme or enzyme inhibitor within the test sample.

Growing community of inventors

Alpharetta, GA, United States of America

Shu-Ping Yang